A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer by Jie Shen et al.
Shen et al. Journal of Translational Medicine 2013, 11:73
http://www.translational-medicine.com/content/11/1/73RESEARCH Open AccessA three-gene signature as potential predictive
biomarker for irinotecan sensitivity in gastric
cancer
Jie Shen1, Jia Wei1, Hao Wang2, Guofeng Yue3, Lixia Yu1, Yang Yang1, Li Xie1, Zhengyun Zou1, Xiaoping Qian1,
Yitao Ding2, Wenxian Guan2* and Baorui Liu1*Abstract
Objective: Personalized chemotherapy based on molecular biomarkers can maximize anticancer efficiency. We aim
to investigate predictive biomarkers capable of predicting response to irinotecan-based treatment in gastric cancer.
Methods: We examined gene expression of APTX, BRCA1, ERCC1, ISG15, Topo1 and methylation of SULF2 in
formalin-fixed paraffin-embedded gastric cancer tissues from 175 patients and evaluated the association between
gene expression levels or methylation status and in vitro sensitivity to irinotecan. We used multiple linear regression
analysis to develop a gene-expression model to predict irinotecan sensitivity in gastric cancer and validated this
model in vitro and vivo.
Results: Gene expression levels of APTX, BRCA1 and ERCC1 were significantly lower in irinotecan-sensitive gastric
cancer samples than those irinotecan-resistant samples (P < 0.001 for all genes), while ISG15 (P = 0.047) and Topo1
(P = 0.002) were significantly higher. Based on those genes, a three-gene signature were established, which was
calculated as follows: Index =0.488 - 0.020× expression level of APTX + 0.015× expression level of Topo1 - 0.011 ×
expression level of BRCA1. The three-gene signature was significantly associated with irinotecan sensitivity (rho = 0.71,
P < 0.001). The sensitivity and specificity for the prediction of irinotecan sensitivity based on the three-gene signature
reached 73% and 86%, respectively. In another independent testing set, the irinotecan inhibition rates in gastric
samples with sensitive-signature were much higher than those with resistant-signature (65% vs. 22%, P < 0.001).
Irinotecan therapy with 20 mg/kg per week to immunodeficient mice carrying xenografts with sensitive-signature
dramatically arrested the growth of tumors (P < 0.001), but had no effect on mice carrying xenografts with
resistant-signature.
Conclusions: The three-gene signature established herein is a potential predictive biomarker for irinotecan
sensitivity in gastric cancer.
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Gastric cancer remains one of the leading causes of can-
cer death worldwide [1,2]. There is no “gold standard”
chemotherapy for advanced gastric cancer up to now. In
recent years, new generation chemotherapy agents, such
as docetaxel, oxaliplatin, irinotecan, capecitabine and S-1
have been studied in phase III studies [3]. However, the
median survival remained below one year [2], and the
response rate was only approximately 30%-50% [4].
Irinotecan (CPT-11) is a semisynthetic derivative of
camptothecin (CPT) which interferes with DNA replica-
tion and cell division through its potent interaction with
the enzyme topoisomerase I (Topo1). Both irinotecan
and CPT belong to Topo1 inhibitors. Irinotecan is mainly
used in colorectal cancer and also frequently used in the
treatment of gastric cancer, showing response rates vary-
ing from 14% to 23% as single agent and approximately
50% in combination [5].
A number of molecular biomarkers capable of pre-
dicting the probability of response to chemotherapeutic
agents have been investigated over the last decades [6].
Our previous studies have identified breast cancer suscep-
tibility gene 1 (BRCA1) as potential predictive biomarker
for cisplatin and docetaxel sensitivity [7,8], thymidylate
synthase (TS) for 5-FU and raltitrexed [9,10], and excision
repair cross-complementing 1 (ERCC1) for platinum [11].
However, there has been limited progress in the identifica-
tion of biomarkers capable of predicting response to
irinotecan-based treatment in gastric cancer. Topo1 regu-
lates DNA supercoiling during replication through the
way of causing single-strand breaks and religation [12].
Irinotecan and its active metabolite SN-38 induce DNA
damage by stabilizing a transient covalent complex be-
tween DNA and Topo1, which then results in DNA strand
breaks, replication arrest, and apoptosis [13]. High tumor
levels of Topo1 protein have recently been reported to
identify a subgroup of metastatic colorectal cancer pa-
tients with good response to irinotecan [14]. Repair of
irinotecan-associated and Topo1-mediated DNA damage
requires removal of the stalled Topo1 and resolution of
the associated DNA break. During this process, a variety
of repair proteins, including aprataxin (APTX), BRCA1
and ERCC1, are involved, some of which may have clinical
potential as predictive biomarkers [15].
Besides of the candidate biomarkers mentioned above,
recent studies suggested that the methylation of the
heparan sulfate 6-O-endosulfatase (SULF2) promoter
was associated with sensitivity to Topo1 inhibitors in
Non-Small-Cell Lung Cancer (NSCLC) [16]. INF-inducible
regulator of ubiquitination (ISG15) could block the
ubiquitin/26S proteasomal pathway leading to accu-
mulation of CPT-induced DNA damage which resulted
in an increased apoptosis [17]. SULF2 methylation(SULF2M) and high ISG15 expressing NSCLC cell
lines showed 134-fold sensitivity to CPT than SULF2
unmethylation (SULF2U) and low ISG15 expressing
cell lines [16].
Based on the above evidences, we hypothesized that
APTX, BRCA1, ERCC1, ISG15, SULF2, and Topo1 or
their combination might play important roles in pre-
dicting irinotecan sensitivity in gastric cancer. In the
current study, we investigated each gene as predictive
biomarker by itself, and then established algorithm
combining those genes together to more accurately pre-
dict irinotecan sensitivity. We also validated the model
in another independent set of gastric cancer samples
and two cohorts of immunodeficient mice models. The
aim of this study was to identify a clinically useful clas-
sification signature that could predict the irinotecan
sensitivity in gastric cancer.
Materials and methods
Patient samples
All specimens and relevant clinical data were obtained
from the department of oncology and general surgery,
Drum Tower Hospital Affiliated to Medical School of
Nanjing University during the period from August 2010
to June 2012. The specimens include 175 freshly-removed
gastric tumors, which were randomly classified as either
training set (n = 100) or testing set (n = 75) by using
computer-generated random numbers. Each tumor tissue
was divided into two parts once it removed in the surgery:
(1) one part was kept in 4°C Hanks’ balanced salt solution
with 1% penicillin/streptomycin and detected chemo-
sensitivity in vitro by histoculture drug response assay
(HDRA); (2) the rest part was left in formalin and made
into formalin-fixed paraffin-embedded (FFPE) tumor
blocks for pathological observation and gene detection.
Diagnosis of patients with gastric tumor was confirmed by
histopathology. Clinical and histopathological data, in-
cluding age, sex, histology, tumor site, stage, histological
grade and lymph node metastasis were all collected. Clin-
ical characteristics of the patients were summarized in
Table 1. Informed consent was obtained from all patients
and the protocols for this study were approved by the Hu-
man Research Protective Committee of Drum Tower
Hospital Affiliated to Medical School of Nanjing University.
All animal experiments were performed in accordance with
the Chinese Coordinating Committee on Cancer Research
Regulations for the Welfare of Animals and the Animal
Protection Law.
HDRA
HDRA procedures were performed as described previ-
ously [18]. Briefly, the fresh tumor tissues were washed
and minced into small pieces to approximately 0.5 mm









63 (29–83) 63 (29–83) 63 (29–83)
≥ 63 51 (51%) 40 (53%) 91 (52%)
< 63 49 (49%) 35 (47%) 84 (48%)
Sex
Male 74 (74%) 57 (76%) 131 (75%)




34 (34%) 28 (37%) 62 (35%)
Proximal
stomach
41 (41%) 29 (39%) 70 (40%)
Whole
stomach
25 (25%) 18 (24%) 43 (25%)
Stage
I 13 (13%) 7 (9%) 20 (11%)
II 20 (20%) 21 (28%) 41 (23%)
III 65 (65%) 45 (60%) 110 (63%)
IV 2 (2%) 2 (3%) 4 (3%)
Histological
grade
2 20 (20%) 16 (21%) 36 (21%)
3 47 (47%) 34 (46%) 81 (46%)
Mixed 1–2 3 (3%) 3 (4%) 6 (3%)
Mixed 2–3 30 (30%) 22 (29%) 52 (30%)
Lymph node
metastasis
No 21 (21%) 19 (25%) 40 (23%)
Yes 79 (79%) 56 (75%) 135 (77%)
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gen (Health Design, Rochester, NY) surfaces in 24-well
microplates. There were 8 parallel culture wells for
irinotecan sensitivity testing and 8 parallel culture wells
for control. After incubation for 7 days at 37°C (in a
humidified atmosphere containing 95% air −5% CO2) in
the presence of drugs dissolved with RPMI 1640
medium containing 20% fetal calf serum, 100 μl type I
collagenase (0.1 mg/ml, Sigma) and MTT (5 mg/ml,
Sigma) were added to each culture well and incubated
for another 16 hours. Concentration of irinotecan was
20 μg/ml according to its peak plasma concentration
(ppc) in patients [19]. After extraction with dimethyl
sulfoxide (DMSO, Sigma), absorbance of the solution in
each well was read at 540 nm. Absorbance per gram of
cultured tumor tissue was calculated from the mean
absorbance of tissue from 8 parallel culture wells, and
the tumor-tissue weight was determined before culture.The inhibition rate was calculated by using the following
formula:
Inhibition rate %ð Þ ¼ 1 T=Cð Þ  100%
T is the mean absorbance of treated tumor/Weight
C is the mean absorbance of control tumor/Weight
mRNA expression level detection
Total RNA extraction from FFPE tissue
Six 7-μm sections were prepared from FFPE tumor
blocks that contained at least 80% tumor cells. After
hematoxylin-eosin staining, the cancerous parts were
microdissected and transferred into a microcentrifuge
tube. RNA was isolated in accordance with a proprietary
procedure (European patent number EP1945764-B1).
Briefly, paraffin was removed by xylene, and micro-
dissected cancerous parts were lysed in a proteinase
K-containing buffer at 60°C for 16 h. RNA was purified
by phenol and chloroform extractions followed by precipi-
tation with isopropanol in the presence of sodium acetate
at −20°C. The RNA pellet was washed in 70% ethanol and
resuspended in 53 μl of RNase-free water followed by
treatment with DNase I (Life Technologies).
QPCR assessment of gene expression
M-MLV Reverse Transcriptase Kit (Invitrogen) was applied
to generate cDNA for Quantitative polymerase chain reac-
tion (qPCR) to detect the β-actin (ACTB), APTX, BRCA1,
ERCC1, ISG15 and Topo1. Each batch of reaction included
a positive control from commercial human lung and liver
RNA (Stratagene, La Jolla, CA, USA) as calibrators and
negative controls without RNA and reverse transcriptase.
Total RNA 1 μg was used for each RT reaction. Template
cDNA was amplified with specific primers and probes
for ACTB, APTX, BRCA1, ERCC1, ISG15 and Topo1
using Taqman Universal Master Mix (Applied Biosystems,
Foster City, CA). The Assay IDs (Applied Biosystems,
Foster City, CA) for the primers and probes were as fol-
lows: Hs99999903_m1 (ACTB), Hs00214452_m1 (APTX),
Hs00157415_m1 (ERCC1), Hs00192713_m1 (ISG15),
Hs00243257_m1 (Topo1), BRCA1 (NM_007294): for-
ward 5’ GGCTATCCTCTCAGAGTGACATTTTA 3’,
reverse 5’ GCTTTATCAGGTTATGTTGCATGGT 3’,
and probe 6FAM −5’ CCACTCAGCAGAGGG 3’ MGB.
QPCR was performed to quantify gene expression using
the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems). The PCR conditions were 50°C
for 2 min, 95°C for 15 min, followed by 40 cycles at
95°C for 15 s and 60°C for 1 min. Relative gene expres-
sion quantifications were calculated according to the
comparative Ct method using ACTB as an endogenous
control, based on our previous experience comparing
different housekeeping genes [7,20], and commercial
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USA) as calibrators, which enables us to compare gene
expression levels between different patients. Final re-
sults were determined by the formula mRNA expression
level = 2-(dCt sample-dCt calibrator) (dCt = Ctgene- CtACTB) [7,21]
and were analyzed with the Stratagene analysis software.
DNA methylation detection
DNA extraction and modification Three 7-μm sec-
tions were prepared from primary tumor blocks that
contained at least 80% tumor cells. After hematoxylin-
eosin staining, the cancerous parts were microdissected
and transferred into a microcentrifuge tube. DNA was
isolated routinely and then was chemically modified by
sodium bisulphite to convert all unmethylated cytosines
to uracils while leaving methylcytosines unaltered [16].
Then they were stored at −20°C for further analysis.
Methylation-specific polymerase chain reaction (MSP)
MSP was performed to determine the methylation of
SULF2 using the ABI Prism 7300HT Sequence Detec-
tion System (Applied Biosystems). Each PCR reaction
contained genomic DNA 2 μl, SYBR Green PCR Mix
(TaKaRa, Japan) 10 μl, water 7.7 μl, and primers 0.15 μl
(10 μmol/ l). The PCR conditions were 95°C for 10 min,
followed by 45 cycles at 59°C for 30 s, 72°C for 30 s and
95°C for 30 s. Primers for SULF2 methylated PCR
(TaKaRa, Japan) were as follows: forward 5’ TAAGT
GTTTTTTTTATAGCGGC 3’, reverse 5’TACCGTAAT
TTCCGCTATC 3’. Primers for SULF2 unmethylated PCR
(TaKaRa, Japan) were as follows: forward 5’ GTTTA
TAAGTGTTTTTTTATAGTGGT3’, reverse 5’TACCATA
ATTTCCACTATCCCT 3’. Each batch of reaction in-
cluded a positive control from Methyltransferase (M.SssI)-
treated human genomic DNA (fully methylated), a negative
control from DNA samples which has been confirmed
unmethylated and another negative control without DNA.
All tests were performed in duplicate.
The establishment and validation of the gene-expression
model for irinotecan sensitivity prediction
We adopted multiple linear regression analysis to establish
the optimized gene-expression model based on the training
set of 100 gastric cancers [22]. According to the results of
stepwise regression (entry: α= 0.10, remove: α = 0.15), model
consisted of APTX, Topo1 and BRCA1 is the optimized
one. We assigned each patient an index according to the lin-
ear combination of the expression level of the mRNA
weighted by the regression coefficient from the training
samples. The index of the gene-expression model was calcu-
lated as follows: Index =0.488 - 0.020× expression level of
APTX+ 0.015× expression level of Topo1 - 0.011 × expres-
sion level of BRCA1. This model was later validated inanother independent testing set of 75 patients with gastric
cancer. In the testing set, patients were ranked according to
their gene signature index and divided into sensitive-
signature and resistant-signature groups by using the me-
dian index as the cutoff point. The irinotecan sensitivity of
these two groups were tested by HDRA and compared with
each other.In vivo validation of the gene-expression model for
irinotecan sensitivity prediction
To establish immunodeficient mice models with patient-
derived gastric cancer xenografts, each freshly-removed
surgical tumor tissue was cut into pieces of 3 × 3 ×
3 mm3, which were transplanted within 30 min to 12
athymic immunodeficient mice, termed a “cohort” [23].
In each cohort, when the tumor grew to a size of
50–100 mm3, mice with xenografts were randomized
to treatment with irinotecan 20 mg/kg/w, ip (n = 6) or
no treatment as the control (n = 6). Individual tumor
volumes (V) were calculated by the formula “V = (length ×
width × width)/2” and compared to the values at the start
of treatment to obtain the relative tumor volume. Mice
were observed every other day for tumor growth.
In order to evaluate the consistent inhibition of
irinotecan in the sensitive-signature mice, three weeks
after first administration, all the tumors were separated
from the first generation mice and passaged to second
generation mice. In the second generation, no drug was
administrated. Mice were observed every day for another
two weeks.Statistical analysis
The Mann–Whitney U-test and the Kruskal-Wallis test
were used to test the association between mRNA expres-
sion levels and clinical characteristics, and the association
between irinotecan sensitivity and patients’ clinicopatho-
logical parameters. The Spearman’s rank method was used
to assess the correlation of the mRNA expression levels
between different genes as well as the correlation be-
tween mRNA levels and in vitro irinotecan sensitivity.
The Mann–Whitney U-test was used to compare
irinotecan sensitivity between SULF2M and SULF2U
groups, irinotecan-sensitive and irinotecan-resistant pa-
tients and between sensitive-signature and resistant-
signature groups. Receiver operating characteristic (ROC)
curves were generated to calculate the sensitivity and spe-
cificity of prediction based on different genes and the
gene-expression model in terms of irinotecan sensitivity.
Paired Student’s t test was used to evaluate the differences
between the tumor sizes of sensitive-signature mice or
resistant-signature mice and controls. A P < 0.05 was con-
sidered statistically significant (two-sided). Statistical ana-
lysis was performed using the SPSS, version 16.0.
Figure 1 Gene expression levels of APTX, BRCA1, ERCC1, ISG15
and Topo1 in 175 patients analyzed by quantitative RT-PCR.
Values of gene expression were calculated according to the
comparative Ct method using ACTB as an endogenous control. The
blue line stood for mean with 95% CI.
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Patient characteristics
Characteristics of all patients are shown in Table 1. In
the 175 patients, the majority of patients were males
(75%), and the histology of every sample was adenocar-
cinoma. In 62 (35%) patients, the tumor was located in
the distal stomach, in 70 (40%) in the proximal stomach,
and in 43 (25%) in the whole stomach. One hundred
and ten (63%) patients had stage III disease. Lymph node
metastasis was present in 135 (77%) patients.
Gene expression levels
The mRNA expression levels of APTX, BRCA1, ERCC1,
ISG15 and Topo1 were detected in all tumors, with me-
dian gene expression level relative to housekeeping
ACTB of 4.32 for APTX (range 0.26–17.99, 95% confi-
dence interval (CI): 3.78–5.19), 7.91 for BRCA1 (range
0.37–29.04, 95% CI: 7.07–9.51), 14.03 for ERCC1
(range 0.33–46.30, 95% CI: 13.01–17.07), 5.07 for ISG15
(range 0.04–34.24, 95% CI: 3.94–6.21), and 7.51 for
Topo1 (range 1.07–37.81, 95% CI: 6.38–9.17) (Figure 1). A
significant association was observed between APTX
mRNA expression levels and histological grade (P = 0.03),
and ISG15 mRNA and gender (P = 0.017). No other asso-
ciation between clinical characteristics and tumor mRNA
levels was found (Table 2). However, a strong correlation
was observed between the mRNA expression levels
of APTX and BRCA1 (rho = 0.53, P < 0.001), APTX
and ERCC1 (rho = 0.73, P < 0.001), BRCA1 and ERCC1
(rho = 0.48, P < 0.001) in tumor.
The relationship between gene expression and
chemosensitivity to irinotecan
In the training set, the irinotecan sensitivity was suc-
cessfully tested in all tumors, with median inhibition rate
of 43.3% (range 2%–89%, CI: 39%–47%). There was no
significant association between irinotecan sensitivity and
clinical characteristics (Table 3), including age (P = 0.51),
sex (P = 0.77), tumor site (P = 0.64), stage (P = 0.41),
histological grade (P = 0.48) and lymph node metastasis
(P = 0.47). However, mRNA levels of APTX (rho = −0.48,
P < 0.001), BRCA1 (rho = −0.49, P < 0.001), ERCC1
(rho = −0.42, P < 0.001), ISG15 (rho = 0.34, P = 0.001),
and Topo1 (rho = 0.43, P < 0.001) showed a correlation to
irinotecan sensitivity. Patients were ranked according
to their irinotecan inhibition rates and divided into
irinotecan-sensitive and irinotecan-resistant groups by
using the median inhibition rate as the cutoff point
[19]. Gene expression levels of APTX (P < 0.001), BRCA1
(P < 0.001) and ERCC1 (P < 0.001) were significantly lower
in irinotecan-sensitive patients than in irinotecan-resistant
patients, while ISG15 (P = 0.047) and Topo1 (P = 0.002)
were significantly higher (Figure 2A-E). ROC curves were
generated to calculate the sensitivity and specificity of theeach gene in predicting irinotecan sensitivity (Figure 2G-J).
The areas under the ROC curve (AUC), sensitivity and
specificity for the prediction of irinotecan sensitivity based
on APTX, BRCA1, ERCC1, ISG15 and Topo1 mRNA
levels were listed in Table 4.
The relationship between SULF2 methylation and
sensitivity to irinotecan
In the training set, the methylation status of SULF2 was
successfully detected in all patients, with thirty-three
(28%) carrying SULF2M and eighty-four (72%) carrying
SULF2U. There was no significant association between
SULF2 methylation status and clinical characteristics.
The irinotecan inhibition rates were 49.8% (range 2%–
89%, 95% CI: 41%–59%) for SULF2M group, and 40.2%
for SULF2U group (range 2%–84%, 95% CI: 34%–46%,
P = 0.08).
The establishment of the gene-expression model and its
association with sensitivity to irinotecan
Based on the expression level of five genes and status of
SULF2 methylation, we constructed a signature by mul-
tiple linear regression analysis as mentioned in the
methods. The index of the three-gene signature ranged
from 0.08 to 0.99 with mean value of 0.43 ± 0.16. There
was a significant correlation between the index and
irinotecan sensitivity (rho = 0.71, P < 0.001) (Figure 3A).
ROC curve was generated to calculate the sensitivity and
specificity of the three-gene signature in predicting
irinotecan sensitivity (Figure 3B). The AUC was 0.828
(95% CI: 0.755–0.901, P < 0.001). With the threshold
value of 0.43, the sensitivity and specificity for the pre-
diction of irinotecan sensitivity based on the three-gene
signature reached 73% and 86%, respectively.
Table 2 The association of the gene expressions and pathological characteristics
Characteristic No. of
Patients
APTX mRNA BRCA1 mRNA ERCC1 mRNA ISG15 mRNA Topo1 mRNA
mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Age, y
≥ 63 91 (52%) 4.81 ± 3.78 8.61 ± 5.73 15.28 ± 10.01 4.48 ± 3.69 8.03 ± 7.30
< 63 84 (48%) 4.09 ± 3.76 7.90 ± 5.95 14.75 ± 9.28 5.79 ± 6.90 7.47 ± 5.81
Sex
Male 131 (75%) 4.77 ± 3.33 8.41 ± 5.57 15.74 ± 10.19 5.54 ± 5.62 7.95 ± 7.17
Female 44 (25%) 3.58 ± 3.29 7.92 ± 6.67 12.77 ± 7.30 3.53 ± 4.27* 7.21 ± 4.62
Tumor Site
Distal stomach 62 (35%) 4.79 ± 2.87 8.97 ± 6.52 16.12 ± 10.36 7.05 ± 7.75 8.09 ± 5.93
Proximal stomach 70 (40%) 4.16 ± 3.10 8.33 ± 5.72 13.97 ± 9.09 3.61 ± 2.64 7.40 ± 6.63
Whole stomach 43 (25%) 4.60 ± 4.44 7.12 ± 4.74 15.31 ± 9.70 4.61 ± 3.43 7.06 ± 7.94
Stage
I 20 (11%) 4.25 ± 4.47 5.91 ± 3.40 13.40 ± 7.07 1.89 ± 0.83 5.89 ± 4.03
II 41 (23%) 4.19 ± 3.01 8.58 ± 5.09 14.70 ± 9.56 6.76 ± 7.96 8.91 ± 6.35
III 110 (63%) 4.66 ± 3.38 8.19 ± 5.75 15.56 ± 10.16 4.67 ± 4.01 7.70 ± 7.07
IV 4 (3%) 4.20 ± 4.61 15.88 ± 17.90 11.01 ± 5.00 7.25 ± 6.33 4.03 ± 1.63
Histological grade
2 36 (21%) 5.05 ± 3.54* 10.97 ± 7.33 15.78 ± 9.52 4.86 ± 4.75 8.08 ± 6.61
3 81 (46%) 3.92 ± 3.55 7.81 ± 5.16 14.30 ± 9.64 3.68 ± 2.75 7.18 ± 6.08
Mixed 1–2 6 (3%) 3.63 ± 4.51 7.17 ± 2.13 15.17 ± 12.40 8.00 ± 8.94 8.42 ± 6.02
Mixed 2–3 52 (30%) 4.55 ± 2.53 7.06 ± 5.27 15.65 ± 9.96 7.16 ± 7.74 8.44 ± 7.18
Lymph node metastasis
No 40 (23%) 4.58 ± 3.39 8.70 ± 5.08 14.68 ± 7.31 5.97 ± 8.17 7.48 ± 4.47
Yes 135 (77%) 4.46 ± 3.35 8.16 ± 6.05 15.16 ± 10.33 4.78 ± 4.12 7.87 ± 7.23
* P < 0.05.
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testing set
To determine if the three-gene signature could signifi-
cantly distinguish the sensitive and resistant group to
irinotecan, we applied it to an independent testing set in-
cluding 75 gastric adenocarcinomas. All the patients’ char-
acteristics were listed in Table 1. In the testing set, the
irinotecan sensitivity was successfully tested in all tumors,
with median inhibition rate of 44.0% (range 2%–89%, CI:
37%–51%). There was no significant association between
irinotecan sensitivity and clinical characteristics (Table 3),
including age (P = 0.54), sex (P = 0.81), tumor site (P =
0.54), stage (P = 0.61), histological grade (P = 0.52) and
lymph node metastasis (P = 0.79). The mRNA expression
levels of APTX, BRCA1, ERCC1, ISG15 and Topo1 were
detected in all tumors and the gene signature index was
calculated as mentioned above. We divided those patients
into two groups according to their gene signature index
(sensitive-signature group: index > 0.43, n = 37; resistant-
signature group: index ≤ 0.43, n = 38). The irinotecan in-
hibition rates in gastric samples with sensitive-signature
were much higher than those with resistant-signature(65% vs. 22%, P < 0.001) (Table 3, Figure 3C). There was a
significant correlation between the index and irinotecan
sensitivity (rho = 0.79, P < 0.001). ROC curve was gener-
ated to calculate the sensitivity and specificity of the
three-gene signature in predicting irinotecan sensitivity in
this set of patients. The AUC was 0.939 (95% CI: 0.882–
0.996, P < 0.001). With the threshold value of 0.43, the
sensitivity and specificity for the prediction of irinotecan
sensitivity based on the three-gene signature reached 84%
and 94%, respectively.
In vivo validation of the three-gene signature
Twenty cohorts of immunodeficient mice (12 mice per
cohort, 240 mice in total) with human-derived xenografts
were successfully established from the 75 surgical speci-
mens of the independent testing set. Based on the mRNA
expression of APTX, BRCA1 and Topo1, one cohort of
mice (n = 12) carrying surgical tumors with sensitive-
signature (Index = 0.95, gene expression level: APTX =
1.01, BRCA1 = 2.78 and Topo1 = 33.96) and another cohort
(n = 12) with resistant-signature (Index = 0.28, gene expres-
sion level: APTX = 8.33, BRCA1 = 6.87 and Topo1 = 2.09)












≥ 63 42% (36–47%) 44% (31–57%)
< 63 45% (39–51%) 44% (34–54%)
Sex
Male 43% (38–47%) 42% (33–51%)
Female 45% (36–55%) 50% (31–68%)
Tumor Site
Distal stomach 42% (35–49%) 44% (28–60%)
Proximal
stomach
44% (38–51%) 47% (35–58%)
Whole stomach 43% (35–51%) 37% (16–59%)
Stage
I 34% (21–47%) 36% (3–70%)
II 49% (40–57%) 50% (31–68%)
III 43% (38–48%) 44% (34–54%)
IV 33% 34%
Histological grade
2 41% (33–49%) 44% (21–68%)
3 42% (36–48%) 39% (27–51%)
Mixed 1–2 54% 58%
Mixed 2–3 46% (38–54%) 49% (35–62%)
Lymph node
metastasis
No 42% (33–51%) 46% (27–65%)
Yes 44% (39–48%) 44% (34–53%)
Signature index
> 0.43 57% (52–63%) ** 65% (61–70%) **
≤ 0.43 31% (27–36%) 22% (17–28%)
** P < 0.001.
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ture. There were 12 mice in each cohort (six for irinotecan
administration and six for control). Irinotecan therapy with
20 mg/kg per week to immunodeficient mice carrying
xenografts with sensitive-signature was well tolerated and
dramatically arrested the growth of tumors (P < 0.001,
Figure 4A), but there was no effect for the same treatment
on mice carrying xenografts with resistant-signature
(P = 0.83, Figure 4B).
Three weeks after first irinotecan administration, all
the tumors were separated from the first generation
mice and passaged to the second generation. There were
in total three groups in the second generation: micecarrying xenografts with sensitive-signature and having
been treated with irinotecan (named “sensitive-signature
mice” for short, n = 6), mice carrying xenografts with
resistant-signature and having been treated with
irinotecan (named “resistant-signature mice” for short,
n = 6) and the controls (no irinotecan administration be-
fore, n = 6). The subsequent tumor size in sensitive-
signature mice kept exhibiting a reduced tumor size
compared with the tumor size in resistant-signature
and control groups (sensitive-signature mice vs. control:
P < 0.001; resistant-signature mice vs. control: P = 0.10,
Figure 4C).
Discussion
The screening and validation of molecular biomarkers
capable of predicting response to different chemothera-
peutic agents constitutes a significant step towards per-
sonalized treatment for cancer patients. In the field of
prognostic biomarkers, advances in genome-wide se-
quencing and microarray analysis have allowed the iden-
tification of molecular signatures that can promote more
precise classification and prognostication of human can-
cers [24-26]. It was reported that a five-gene signature
was closely associated with relapse-free and overall sur-
vival among patients with NSCLC, and a 54-gene signa-
ture could predict the risk of recurrence in NSCLC [25].
A 21-gene signature also has been demonstrated to pre-
dict the risk of distant recurrence in postmenopausal
patients with breast cancer treated with anastrozole or
tamoxifen [26]. However, up to now, in the field of
chemosensitivity predictive biomarkers, there is still no
such gene signature for personalizing chemotherapy in
gastric cancer.
In the present study, we firstly investigated the value
of APTX, BRCA1, ERCC1, ISG15, SULF2 and Topo1 as
predictive biomarkers to irinotecan, respectively. We
found that although those genes had correlation with
irinotecan sensitivity, their function in irinotecan sensi-
tivity prediction was limited and their combination
might improve efficiency. Therefore, we established a
three-gene signature by multiple linear regression ana-
lysis and demonstrated the promising value of this signa-
ture in distinguishing two subgroups of advanced gastric
cancer patients that widely differed in their sensitivity to
irinotecan treatment. Moreover, validation was carried
out in another independent testing set and two cohorts
of immunodeficient mice models with patient-derived
gastric cancer xenografts. It was showed that samples
with sensitive-signature were significantly more sensitive
to irinotecan than those with resistant-signature. Immu-
nodeficient mice model with human-derived xenograft
also showed that mice with sensitive-signature (high
three-gene signature index) could benefit from irinotecan
therapy dramatically and were delayed in tumor growth in
Figure 2 Gene expression levels of APTX (P < 0.001), BRCA1 (P < 0.001) and ERCC1 (P < 0.001) were significantly lower in irinotecan-
sensitive patients than in irinotecan-resistant patients, while ISG15 (P = 0.047) and Topo1 (P = 0.002) were significantly higher. Box plots
showed the mRNA expression levels of APTX (A), BRCA1 (B), ERCC1 (C), ISG15 (D) and Topo1 (E) in irinotecan-sensitive and irinotecan-resistant
groups, respectively (n = 100). The lines inside the boxes denoted the medians. The whiskers of box plots: Min to Max. Graphs of ROC curve
showed the AUCs of APTX (F), BRCA1 (G), ERCC1 (H), ISG15 (I) and Topo1 (J) for predicting irinotecan sensitivity. Sensitivity (Y-axis) was plotted
against false-positive fraction (1 - specificity).
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signature (low three-gene signature index) had no re-
sponse to irinotecan and their tumor kept growing in both
first and second generation. Taken together, these findings
indicate that this three-gene signature is closely associated
with irinotecan sensitivity among patients with gastric
cancer.
The chemosensitivity assay we adopted in the present
study included HDRA for in vitro testing and immuno-
deficient mice models with patient-derived gastric cancer
xenografts for in vivo validation. HDRA has been dem-
onstrated by varieties of studies as a useful predictor for
chemosensitivity at different cancerous sites, including
gastrointestinal cancer [18]. It has been reported in gas-
tric cancer[18], esophageal cancer [19], breast cancer
[27], oral squamous cell carcinomas [28] and head and
neck cancer [29] that efficacy rate for an individual agent
using HDRA assay in vitro has a considerable good cor-
relation with clinical response rate to each agent. The
value of patient-derived tumor xenograft model has been
investigated and evaluated in various studies, including
retrospective and prospective clinical studies [23,30-33].
Similar to the original tumor sample in histological and
gene status, the response of xenograft models could pre-
dict the efficiency of chemotherapeutic agents in moreTable 4 The sensitivity and specificity of five gene expression





Topo1 Irinotecan 48%than 90% patients [23,30]. Good correlations between ef-
ficacy rate for an individual agent using such model and
clinical response rate to each agent have been well demon-
strated [31]. A patient with advanced and gemcitabine-
resistant pancreatic cancer resulted in long-lasting tumor
response after the efficient treatment guided by the per-
sonalized xenograft model generated from the patient’s
freshly-removed tumor [32]. In another pilot clinical
study, patients with advanced cancer were treated with 17
selected regimens on the basis of personalized tumor
grafts. Consequently, durable partial remissions were ob-
served in 15 cases [33]. These results supported the notion
of patient-derived tumor xenograft models as a powerful
platform for chemosensitivity evaluation. In present study,
we established different cohorts of immunodeficient mice
models with patient-derived gastric cancer xenografts,
and demonstrated that tumor growth were significantly
suppressed in the cohort with sensitive-signature (low
APTX and BRCA1, but high Topo1 mRNA expression
level, Index = 0.95) when treated with irinotecan, but had
no differences compared with cohort with resistant-
signature (high APTX and BRCA1, but low Topo1 mRNA
expression level, Index = 0.28). The results of the second
generation tumor showed that irinotecan might have anti-
cancer efficiency on stem-like cells and therefore thelevels for the prediction of irinotecan sensitivity
Specificity AUC (95% CI) P
74% 0.758 (0.669-0.847) <0.001
58% 0.760 (0.673-0.846) < 0.001
79% 0.726 (0.632-0.821) <0.001
73% 0.617 (0.494-0.740) 0.047
94% 0.664 (0.563-0.765) 0.002
Figure 3 The evaluation and validation of the three-gene signature for irinotecan sensitivity prediction. A, there was a significant
association between the three-gene signature index and irinotecan sensitivity (rho = 0.71, P < 0.001). Index (Y-axis) was plotted against irinotecan
inhibition rate. “0.00” stood for no inhibition, while “1.00” stood for 100% inhibition. B, ROC curve was made for irinotecan sensitivity prediction
based on the three-gene signature index. Sensitivity (Y-axis) was plotted against false-positive fraction (1 - specificity). The AUC was 0.828 (95% CI:
0.755–0.901, P < 0.001). C, the irinotecan inhibition of gastric samples with sensitive-signature was much higher than those with resistant-
signature (65% vs. 22%, P < 0.001). Sensitive-signature group: three-gene signature index > 0.43, n = 37; resistant-signature group:
index≤ 0.43, n = 38.
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sensitive-signature group.
We have to admit that HDRA and mice model might
still not be representative of the behavior of the patient’s
tumors because of the cancer heterozygote and patients’
characteristics, such as age, gender, tumor size and loca-
tion. There may unavoidably be an imperfect relationship
between tumor response and survival because of treatment
associated adverse events. In order to avoid tumor hetero-
geneity, we designed 8 parallel culture wells for irinotecan
sensitivity testing and 8 parallel culture wells for control
from different parts of one patient’s tumor sample. The
mice models we have established were derived from 75 pa-
tients with different clinicopathological parameters. We
will follow up those patients to confirm that whether this
in vivo and in vitro inhibition would have consequences for
the therapy as well as patients’ outcome.
Gene-expression signature usually established by the
use of microarrays and later validated by qPCR [24].
However, in clinical practice, microarrays usually involv-
ing a large number of genes in the analysis are limited
by complicated methods, lack of reproducibility, the
need for fresh-frozen tissues and further indepen-
dent validation of the results [34]. RT-PCR comprising a
smaller number of genes may be more clinically useful,
allowing for reproducible and accurate quantification of
results for small amounts of RNA obtained from FFPE
specimens [24,34]. In the current study, we firstly selected
six candidate predictive biomarkers for irinotecan based
on widely literature review and previous investigation, and
then RT-PCR were performed for gene detection and fur-
ther analysis. The method we adopted to detect mRNA
expression levels in FFPE specimens is feasible for routine
gene expression analysis in daily clinical practice.According to the results of stepwise regression, the
predictive model we established consists of three genes
(APTX, BRCA1 and Topo1) finally. mRNA levels of
APTX and BRCA1 are both negatively correlated with
irinotecan sensitivity, while Topo1 level is positively cor-
related with irinotecan sensitivity. Irinotecan, as a kind
of Topo1 inhibitors, can stabilize of Topo1-DNA com-
plex that upon collision with the replication fork causes
double-strand DNA breaks, cell cycle arrest and death
[12]. Therefore, the direct molecular target Topo1 was
regarded as the best-characterized biomarker capable of
predicting response to irinotecan [14]. A clinical study
in metastatic colorectal cancer has reported that higher
protein levels of Topo1 were correlated longer overall
survival (17.4 months vs. 14.7 months, P = 0.005) and bet-
ter response to irinotecan significantly [14]. Staying with
the same line of the previous study, the current study
demonstrated that both singly or combined in the three-
gene signature, tumors with higher mRNA levels of Topo1
were more sensitive to irinotecan in gastric cancer.
Irinotecan treatment results in the accumulation of
DNA strand breaks in tumor cells, and APTX, BRCA1
and ERCC1 have been shown to have important roles in
the repair of DNA single- and double-strand breaks [15].
Validation in a panel of 30 colorectal cancer cell lines, the
levels of APTX were significantly associated with CPT
sensitivity (P = 0.004) [35]. It also reported that APTX as a
predictive biomarker was capable of identifying a subset of
advanced colorectal cancer patients with high probability
of response to irinotecan-based treatment. Patients with
low levels of APTX had improved progression-free (9.2 vs.
5.5 months, P = 0.03) and overall survival (36.7 vs. 19 -
months, P = 0.008) [13]. Both BRCA1 and ERCC1 play
central roles in nucleotide excision repair in DNA damage
Figure 4 Response to irinotecan in patient-derived gastric cancer xenografts with different three-gene signature. A, chemosensitivity of
mice model with sensitive-signature (Index = 0.95, gene expression level: APTX = 1.01, BRCA1 = 2.78 and Topo1 = 33.96). B, chemosensitivity of
mice model with resistant-signature (Index = 0.28, gene expression level: APTX = 8.33, BRCA1 = 6.87 and Topo1 = 2.09). Twelve mice per cohort
were treated with the irinotecan or no administration in control as described in Materials and Methods. The black arrow stood for administration
time. Tumor growth was measured every other day, and relative tumor volume (Y-axis) was plotted against time. C, in the second generation, the
subsequent tumor size in sensitive-signature mice kept exhibiting a reduced tumor size compared with the tumor size in resistant-signature and
control groups. Tumor growth was measured every day, and tumor volumes (Y-axis) were plotted against time. SDs were not shown because of
better clarity. Asterisks (★), significance compared with control.
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ential modulators of sensitivity to cisplatin and docetaxel
[7]. BRCA1 was also been reported to be related with the
sensitivity of Topo1 poison in a study of mice model with
mammary tumors [36]. ERCC1 is part of the ERCC1–
ERCC4 (XPF) heterodimeric structure-specific endonucle-
ase, and has been implicated in platinum resistance.
Recently, ERCC1 was also demonstrated by a cell line
study to be involved in repair of CPT-induced DNA dam-
age and had potential value in predicting CPT sensitivity
[37]. As a supplement to the previous studies, the current
study further demonstrated that higher APTX, BRCA1
and ERCC1 mRNA expression levels suggested lowerlikelihood of response to irinotecan-based chemotherapy
in gastric cancer. The three-gene signature with APTX
and BRCA1 could predict sensitivity to irinotecan more
precisely. This may result from the reason that DNA dam-
age caused by irinotecan would be repaired more effi-
ciently when APTX, BRCA1 and ERCC1 expression in
high levels, and therefore, these samples would have a
poor response to this form of treatment. Moreover, the re-
gression coefficient for APTX was higher than for Topo1,
which might indicate that the response to irinotecan in
gastric tumors could highly dependent on DNA repair
mechanisms. The specific mechanisms remain to be fur-
ther studied and elucidated.
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It has been demonstrated that promoter CpG island
methylation of SULF2 is highly prevalent in resected lung
adenocarcinomas and is significantly associated with bet-
ter survival [38]. ISG15 interferes with the ubiquitin/26S
proteasome pathway and increase the sensitivity to Topo1
inhibitors by leading to accumulation of CPT-induced
DNA damage and resulting in an increased level of apop-
tosis [17]. In NSCLC, silencing SULF2 through methyla-
tion could result the significant increase of ISG15 mRNA
expression levels and increase sensitivity to Topo1 inhibi-
tors in vitro [16]. In the present study, based on freshly-
removed gastric tumors, ISG15 was demonstrated to
correlate with irinotecan sensitivity positively. Samples
with higher mRNA expression levels of ISG15 were more
sensitive to irinotecan. Our study also showed that
SULF2M group might have a higher likelihood of benefit
from irinotecan-based treatment than SULF2U group.
Further validation is warranted.
Conclusion
In conclusion, the establishment of this three-gene sig-
nature as a new model predicting the sensitivity to
irinotecan treatment constitutes a new step towards the
goal of individualized treatment for gastric cancer pa-
tients. Our results suggest that a patient with a tumor
that has high levels of the three-gene signature index
would be an ideal candidate to receive single or com-
bined treatment with irinotecan. These findings are pre-
liminary and suggestive at this point, and this three-gene
signature needs to be validated before being used in rou-
tine daily clinical practice. A clinical trial is currently be-
ing designed in order to validate the role of customizing
treatment based on this three-gene signature.
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